The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.

The 'RHOBH' star, whose melanoma spread to her brain and lungs, revealed the survival odds she was given by doctors.

The following is a summary of "A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors ...

"Real Housewives of Beverly Hills" personality Teddi Mellencamp admitted she was "really scared" now that doctors have given her a 50% chance to survive cancer.

Teddi Mellencamp is fighting for her life. The “Real Housewives of Beverly Hills” alum, 43, revealed on “Nightline” Thursday ...

Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine ...

The National Cancer Institute’s Investigational New Drug program facilitates collaboration, not collusion, with industry for ...

The sector has seen billions in merger and acquisition activity in recent years; a September 2024 analysis by Insight ...

A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

Results of a study show convergent genetic adaptation under hypoxia (lack of oxygen) between populations living at ...

Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.